Results 171 to 180 of about 2,631,955 (205)
Some of the next articles are maybe not open access.
Clinical and Translational Oncology, 2021
Immunoscore can effectively predict prognosis in patients with colon cancer; however, its clinical application is limited. We modified the Immunoscore and created a tumor immune microenvironment (TIM) classification system for gastric carcinoma. Unlike previous studies that used small sample sizes or focused on particular immune-cell subtypes, our ...
H. Kim +5 more
openaire +2 more sources
Immunoscore can effectively predict prognosis in patients with colon cancer; however, its clinical application is limited. We modified the Immunoscore and created a tumor immune microenvironment (TIM) classification system for gastric carcinoma. Unlike previous studies that used small sample sizes or focused on particular immune-cell subtypes, our ...
H. Kim +5 more
openaire +2 more sources
Characterization of the tumor mutation burden in hepatobiliary tumors.
Journal of Clinical Oncology, 2019295 Background: Hepatobiliary tumors are aggressive tumors with emerging evidence for increasing sensitivity to immune checkpoint inhibitors (ICI). Tumor mutation burden (TMB) was found to be a quantitative biomarker associated with production of neoantigens within the tumor and predict the sensitivity to immune therapy. Herein, we explore the TMB as
Ramya Thota +7 more
openaire +1 more source
Pediatric Blood & Cancer, 2020
AbstractBackgroundTumor mutational burden (TMB) and driver mutations are potential biomarkers to guide targeted therapy selection. Malignant gliomas with high TMB in children may preferentially benefit from treatment with immune checkpoint inhibitors (ICPIs).
Roshal R. Patel +3 more
openaire +2 more sources
AbstractBackgroundTumor mutational burden (TMB) and driver mutations are potential biomarkers to guide targeted therapy selection. Malignant gliomas with high TMB in children may preferentially benefit from treatment with immune checkpoint inhibitors (ICPIs).
Roshal R. Patel +3 more
openaire +2 more sources
Association of tumor mutational burden with age in solid tumors.
Journal of Clinical Oncology, 2020e13590 Background: Immunotherapy is becoming one of the promising treatments for cancer administration, and several studies indicated a better outcome was received in patients with high tumor mutation burden (TMB). The distribution of TMB is still unknown and this study aimed to analysis the association between TMB and age especially in East Asian ...
Zhuang Yu +8 more
openaire +1 more source
Plasma Tumor Mutation Burden and Response to Pembrolizumab—Letter
Clinical Cancer Research, 2020Predictive biomarkers are critical for patient selection in immune checkpoint inhibitor (ICI) therapy. However, the term “predictive” are often confused with “prognostic,” leading to inappropriate treatment choice in clinical practice and research.
Xiaoyan, Li +3 more
openaire +2 more sources
The emerging development of tumor mutational burden in patients with NSCLC
Future Oncology, 2020Immunocheckpoint inhibitors (ICIs) which target PD-1 and CTLA-4 have dramatically changed the history of non-small-cell lung cancer treatment. Multiple biomarkers especially tumor mutational burden (TMB) have been raised to be potential predictors of response to ICIs.
Yu Zhang +3 more
openaire +2 more sources
The status of tumor mutational burden and immunotherapy
Nature Cancer, 2022Valsamo, Anagnostou +3 more
openaire +2 more sources
Clinical Utility of Solid Tumor Epigenetics
Medical Epigenetics, 2021Sevin Turcan, Julian Taranda
exaly
Brain and Other Central Nervous System Tumor Statistics, 2021
Ca-A Cancer Journal for Clinicians, 2021Rebecca L. Siegel +2 more
exaly